Skip to main content
TipRanks
Go Ultimate75% OFF

Lineage Therap (LCTX) Stock Statistics & Valuation Metrics

2,101 Followers

Total Valuation

Lineage Therap has a market cap or net worth of $201.12M. The enterprise value is $203.33M.

Market Cap
$201.12M
Enterprise Value
$203.33M

Share Statistics

Lineage Therap has 252,954,760 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding
252,954,760
Owned by Insiders
13.78%
Owned by Institutions
45.21%

Financial Efficiency

Lineage Therap’s return on equity (ROE) is -1.43 and return on invested capital (ROIC) is -19.75%.

Return on Equity (ROE)
-1.43
Return on Assets (ROA)
-0.56
Return on Invested Capital (ROIC)
-19.75%
Return on Capital Employed (ROCE)
-0.22
Revenue Per Employee
194.08K
Profits Per Employee
-847.11K
Employee Count
75
Asset Turnover
0.13
Inventory Turnover
0.00

Valuation Ratios

The current PE Ratio of Lineage Therap is 128.29. Lineage Therap’s PEG ratio is 0.59.

PE Ratio
128.29
PS Ratio
19.47
PB Ratio
3.14
Price to FCF
-8.11
Price to Operating Cash Flow
-8.17
PEG Ratio
0.59

Income Statement

In the last 12 months, Lineage Therap had revenue of 14.56M and earned -63.53M in profits. Earnings per share was -0.28.

Revenue
14.56M
Gross Profit
13.71M
Operating Income
-21.78M
Pretax Income
-68.65M
Net Income
-63.53M
EBITDA
-67.95M
Earnings Per Share (EPS)
-0.28

Cash Flow

In the last 12 months, operating cash flow was -25.82M and capital expenditures -185,000, giving a free cash flow of -26.00M billion.

Operating Cash Flow
-25.82M
Free Cash Flow
-26.00M
Free Cash Flow per Share
-0.10

Dividends & Yields

Lineage Therap pays an annual dividend of ―, resulting in a dividend yield of ―

Dividend Per Share
―
Dividend Yield
―
Payout Ratio
N/A
Free Cash Flow Yield
-12.84%
Earnings Yield
0.87%

Stock Price Statistics

Beta
1.01
52-Week Price Change
-57.71%
50-Day Moving Average
1.00
200-Day Moving Average
1.29
Relative Strength Index (RSI)
34.03
Average Volume (3m)
1.53M

Important Dates

Lineage Therap upcoming earnings date is Mar 11, 2027, TBA (Not Confirmed).

Last Earnings Date
Nov 12, 2026
Next Earnings Date
Mar 11, 2027
Ex-Dividend Date
―

Financial Position

Lineage Therap as a current ratio of 5.20, with Debt / Equity ratio of 5.43%

Current Ratio
5.20
Quick Ratio
5.20
Debt to Market Cap
0.00
Net Debt to EBITDA
0.56
Interest Coverage Ratio
0.00

Taxes

In the past 12 months, Lineage Therap has paid -5.11M in taxes.

Income Tax
-5.11M
Effective Tax Rate
0.07

Enterprise Valuation

Lineage Therap EV to EBITDA ratio is -82.62, with an EV/FCF ratio of -6.85.

EV to Sales
16.44
EV to EBITDA
-82.62
EV to Free Cash Flow
-6.85
EV to Operating Cash Flow
-6.90

Balance Sheet

Lineage Therap has $45.18M in cash and marketable securities with $2.03M in debt, giving a net cash position of $43.15M billion.

Cash & Marketable Securities
$45.18M
Total Debt
$2.03M
Net Cash
$43.15M
Net Cash Per Share
$0.17
Tangible Book Value Per Share
$0.09

Margins

Gross margin is 95.88%, with operating margin of -280.34%, and net profit margin of 16.18%.

Gross Margin
95.88%
Operating Margin
-280.34%
Pretax Margin
-26.94%
Net Profit Margin
16.18%
EBITDA Margin
-19.90%
EBIT Margin
-26.94%

Analyst Forecast

The average price target for Lineage Therap is $6.50, which is 11.43% higher than the current price. The consensus rating is Moderate Buy

Price Target
$6.50
Price Target Upside
717.61% Upside
Analyst Consensus
Moderate Buy
Analyst Count
2
Revenue Growth Forecast
0.18%
EPS Growth Forecast
―

Scores

Smart Score
8
AI Score
48